SPONSOR
Shanghai BDgene Co., Ltd.
Total Trials
2
Recruiting
2
Phases
Phase 1
Shanghai BDgene Co., Ltd. is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including β-thalassemia, β-thalassemia Major.
The trial portfolio spans Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Shanghai BDgene Co., Ltd.
How many clinical trials has Shanghai BDgene Co., Ltd. sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Shanghai BDgene Co., Ltd., of which 2 are actively recruiting participants. These trials cover conditions including β-thalassemia, β-thalassemia Major. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Shanghai BDgene Co., Ltd. research focus on?
Shanghai BDgene Co., Ltd. clinical trials span β-thalassemia, β-thalassemia Major. The research pipeline includes Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Shanghai BDgene Co., Ltd. clinical trial?
To participate in a Shanghai BDgene Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Shanghai BDgene Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by Shanghai BDgene Co., Ltd.
NCT06465550 Phase 1
Recruiting
A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
β-thalassemia
NCT05776173
Recruiting
Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia
β-thalassemia Major
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology